Related Experiment Video
Updated: May 14, 2025
09:03
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
8.6K
Progress Update on STING Agonists as Vaccine Adjuvants.
Yanru Shen1, Weijin Huang1,2,3, Jianhui Nie1,2,3
1Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China.
Vaccines
|May 7, 2025
Summary
Stimulator of interferon genes (STING) agonists enhance vaccine immunity by boosting immune responses. Research reviews their use as adjuvants in vaccines against infections and cancer, highlighting the need for safe delivery strategies.
Area of Science:
- Immunology
- Vaccinology
- Drug Development
Background:
- Low antigen immunogenicity limits vaccine efficacy, necessitating potent immune-enhancing adjuvants.
- Stimulator of interferon genes (STING) agonists activate immune cells, inducing type-I interferon responses crucial for vaccine-induced immunity.
Purpose of the Study:
- To review natural and synthetic STING agonists for vaccine development.
- To summarize their application in preventive and therapeutic vaccines.
- To discuss the safety and delivery strategies of STING agonists as vaccine adjuvants.
Main Methods:
- Literature review of preclinical and clinical studies on STING agonists in vaccine development.
- Analysis of STING agonist applications in various vaccine formulations.
- Evaluation of safety profiles and delivery systems for STING agonists.
Main Results:
- STING agonists show promise in enhancing vaccine-induced immunity against infections and cancer.
- Both natural and synthetic STING agonists have been explored as vaccine adjuvants.
- Safety concerns and off-target effects necessitate biocompatible delivery carriers.
Conclusions:
- STING agonists represent a significant advancement in vaccine research, improving immune responses and efficacy.
- Further research is essential to optimize delivery strategies and confirm long-term safety and efficacy in clinical trials.
